Prognostic value of metabolic tumor volume and velocity in predicting head-and-neck cancer outcomes

International Journal of Radiation Oncology Biology Physics

Volumn 83, Issue 5, 2012, Pages 1521-1527

  Chu, Karen P ^a   Murphy, James D ^a   La, Trang H ^a   Krakow, Trevor E ^a   Iagaru, Andrei ^b   Graves, Edward E ^a   Hsu, Annie ^a   Maxim, Peter G ^a   Loo, Billy ^a   Chang, Daniel T ^a   Le, Quynh Thu ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Computed tomography; Functional imaging; Head and neck cancers; Metabolic tumor volume; Positron emission tomography

Indexed keywords

COMPUTED TOMOGRAPHY; COX REGRESSION ANALYSIS; DISEASE PROGRESSION; FUNCTIONAL IMAGING; HAZARD RATIO; HEAD-AND-NECK CANCER; OVERALL SURVIVAL; PRE-TREATMENT; PROGNOSTIC INDICATORS; TUMOR GROWTH; TUMOR VOLUMES;

DISEASES; METABOLISM; PATIENT TREATMENT; PESTICIDE EFFECTS; POSITRON EMISSION TOMOGRAPHY; REGRESSION ANALYSIS; TUMORS; VELOCITY;

COMPUTERIZED TOMOGRAPHY;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC TUMOR VOLUME; OVERALL SURVIVAL; PRIORITY JOURNAL; VELOCITY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; KARNOFSKY PERFORMANCE STATUS; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROPORTIONAL HAZARDS MODELS; RADIOPHARMACEUTICALS; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84862146985     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.10.022     Document Type: Article

References (28)

1. I.F. Ciernik, E. Dizendorf, and B.G. Baumert Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): A feasibility study Int J Radiat Oncol Biol Phys 57 2003 853 863
2. A.J. Fleming Jr. , S.P. Smith Jr. , and C.M. Paul Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients Laryngoscope 117 2007 1173 1179
3. A.C. Paulino, M. Koshy, and R. Howell Comparison of CT- and FDG-PET-defined gross tumor volume in intensity-modulated radiotherapy for head-and-neck cancer Int J Radiat Oncol Biol Phys 61 2005 1385 1392
4. J.F. Daisne, T. Duprez, and B. Weynand Tumor volume in pharyngolaryngeal squamous cell carcinoma: Comparison at CT, MR imaging, and FDG PET and validation with surgical specimen Radiology 233 2004 93 100
5. R.S. Rodrigues, F.A. Bozza, and P.E. Christian Comparison of whole-body PET/CT, dedicated high-resolution head and neck PET/CT, and contrast-enhanced CT in preoperative staging of clinically M0 squamous cell carcinoma of the head and neck J Nucl Med 50 2009 1205 1213
6. J.L. Roh, K.H. Pae, and S.H. Choi 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography as guidance for primary treatment in patients with advanced-stage resectable squamous cell carcinoma of the larynx and hypopharynx Eur J Surg Oncol 33 2007 790 795
7. A.S. Allal, P. Dulguerov, and M. Allaoua Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy J Clin Oncol 20 2002 1398 1404
8. S.W. Lee, S.Y. Nam, and K.C. Im Prediction of prognosis using standardized uptake value of 2-[(18)F] fluoro-2-deoxy-d-glucose positron emission tomography for nasopharyngeal carcinomas Radiother Oncol 87 2008 211 216
9. H. Minn, M. Lapela, and P.J. Klemi Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer J Nucl Med 38 1997 1907 1911
10. T.H. La, E.J. Filion, and B.B. Turnbull Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer Int J Radiat Oncol Biol Phys 74 2009 1335 1341
11. J.D. Murphy, T.H. La, and K. Chu Post-radiation metabolic tumor volume predicts outcome in head-and-neck cancer Int J Radiat Oncol Biol Phys 80 2011 514 521
12. S.H. Hyun, J.Y. Choi, and Y.M. Shim Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma Ann Surg Oncol 17 2010 115 122
13. P. Lee, D.K. Weerasuriya, and P.W. Lavori Metabolic tumor burden predicts for disease progression and death in lung cancer Int J Radiat Oncol Biol Phys 69 2007 328 333
14. Y.M. Seol, B.R. Kwon, and M.K. Song Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy Acta Oncol 49 2010 201 208
15. P. Xie, J.B. Yue, and H.X. Zhao Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma J Cancer Res Clin Oncol 136 2010 883 889
16. D.R. Cox Regression models and life tables J R Stat Soc Series B 34 1972 187 220
17. S. Everitt, A. Herschtal, and J. Callahan High rates of tumor growth and disease progression detected on serial pretreatment fluorodeoxyglucose-positron emission tomography/computed tomography scans in radical radiotherapy candidates with nonsmall cell lung cancer Cancer 116 2010 5030 5037
18. L.K. Shankar, J.M. Hoffman, and S. Bacharach Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials J Nucl Med 47 2006 1059 1066
19. M.E. Juweid, S. Stroobants, and O.S. Hoekstra Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma J Clin Oncol 25 2007 571 578
20. C.M. Lockhart, L.R. MacDonald, and A.M. Alessio Quantifying and reducing the effect of calibration error on variability of PET/CT standardized uptake value measurements J Nucl Med 52 2011 218 224
21. C. Nahmias, and L.M. Wahl Reproducibility of standardized uptake value measurements determined by 18F-FDG PET in malignant tumors J Nucl Med 49 2008 1804 1808
22. T. Hara, T. Higashi, and Y. Nakamoto Significance of chronic marked hyperglycemia on FDG-PET: Is it really problematic for clinical oncologic imaging? Ann Nucl Med 23 2009 657 669
23. Z. Rabkin, O. Israel, and Z. Keidar Do hyperglycemia and diabetes affect the incidence of false-negative 18F-FDG PET/CT studies in patients evaluated for infection or inflammation and cancer? A comparative analysis J Nucl Med 51 2010 1015 1020
24. H.M. Zhuang, A. Cortes-Blanco, and M. Pourdehnad Do high glucose levels have differential effect on FDG uptake in inflammatory and malignant disorders? Nucl Med Commun 22 2001 1123 1128
25. Y. Sugawara, K.R. Zasadny, and A.W. Neuhoff Reevaluation of the standardized uptake value for FDG: Variations with body weight and methods for correction Radiology 213 1999 521 525
26. R.L. Wahl, H. Jacene, and Y. Kasamon From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors J Nucl Med 50 Suppl 1 2009 122S 150S
27. E.J. Chun, H.J. Lee, and W.J. Kang Differentiation between malignancy and inflammation in pulmonary ground-glass nodules: The feasibility of integrated (18)F-FDG PET/CT Lung Cancer 65 2009 180 186
28. K.S. Simons, P. Pickkers, and C.P. Bleeker-Rovers F-18-fluorodeoxyglucose positron emission tomography combined with CT in critically ill patients with suspected infection Intensive Care Med 36 2010 504 511